Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cutaneous and Ocular Toxicology

• Publication date

  2018-04-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/15569527.2017.1375943PMID 28874077
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of MicroRNAs Involved in Resistance to Sunitinib in Renal Cell Carcinoma Cells.

  2017cited by this paper
• MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX

  2017cited by this paper
• A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab

  2016cited by this paper
• Expression and function of microRNA-188-5p in activated rheumatoid arthritis synovial fibroblasts.

  2015cited by this paper
• The Functions of MicroRNAs: mRNA Decay and Translational Repression.

  2015cited by this paper
• Expression and function of microRNA-188-5p in activated rheumatoid arthritis synovial fibroblasts.

  2015cited by this paper
• Comparative Study of Ranibizumab and Bevacizumab on Corneal Neovascularization in Rabbits

  2014cited by this paper
• Corneal endothelial safety following subconjunctival and intrastromal injection of bevacizumab for corneal neovascularization

  2014cited by this paper
• Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab

  2014cited by this paper
• Progress of anti‐vascular endothelial growth factor therapy for ocular neovascular disease: benefits and challenges

  2014cited by this paper
• Sunitinib in the treatment of advanced solid tumors.

  2014cited by this paper
• MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.

  2014cited by this paper
• Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials

  2014cited by this paper
• Long-term outcomes of Fine Needle Diathermy for established corneal neovascularisation

  2014cited by this paper
• Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model.

  2014cited by this paper
• MicroRNA-410 Reduces the Expression of Vascular Endothelial Growth Factor and Inhibits Oxygen-Induced Retinal Neovascularization

  2014cited by this paper
• miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.

  2013cited by this paper
• Osteocyte-induced angiogenesis via VEGF–MAPK-dependent pathways in endothelial cells

  2013cited by this paper
• Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.

  2013cited by this paper
• Ocular neovascularization

  2013cited by this paper
• [Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model].

  2013cited by this paper
• Inhibitory effects of topical cyclosporine A 0.05 % on immune-mediated corneal neovascularization in rabbits

  2013cited by this paper
• Topically administered bevacizumab had longer standing anti-angiogenic effect than subconjunctivally injected bevacizumab in rat corneal neovacularization.

  2013cited by this paper
• The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization

  2013cited by this paper
• Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model.

  2013cited by this paper
• The microRNA-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids

  2013cited by this paper
• Inhibition of Corneal Neovascularization by Subconjunctival and Topical Bevacizumab and Sunitinib in a Rabbit Model

  2013cited by this paper
• Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model

  2013cited by this paper
• Cambios en la morfología y la microdensidad neovascular corneal inducidos tras la administración tópica de bevacizumab y sunitinib en un modelo animal

  2013cited by this paper
• [Corneal neovascularization: epidemiological, physiopathological, and clinical features].

  2013cited by this paper
• Corneal neovascularization: an anti-VEGF therapy review.

  2012cited by this paper
• Topical and Subconjunctival Bevacizumab for Corneal Neovascularization in an Experimental Rat Model

  2012cited by this paper
• Anti-VEGF Treatment of Corneal Neovascularization.

  2011cited by this paper
• Inflammatory Corneal Neovascularization: Etiopathogenesis

  2011cited by this paper
• Treatments for corneal neovascularization: a review.

  2011cited by this paper
• Treatments for Corneal Neovascularization: A Review.

  2011cited by this paper
• Anatomy and physiology of the cornea

  2011cited by this paper
• Corneal penetration of topical and subconjunctival bevacizumab.

  2011cited by this paper
• Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.

  2010cited by this paper
• Corneal transparency: genesis, maintenance and dysfunction.

  2010cited by this paper
• Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration

  2009cited by this paper
• Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles.

  2006cited by this paper
• Ocular angiogenesis: the role of growth factors.

  2006cited by this paper
• Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing.

  2004cited by this paper
• [Neovascularization in ocular tissues: mechanisms and role of proangiogenic and antiangiogenic factors].

  2004cited by this paper
• [Vasculogenesis and angiogenesis].

  2003cited by this paper
• Corneal neovascularization.

  2001cited by this paper
• Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.

  2000cited by this paper
• Ocular neovascularization: an epidemiologic review.

  1998cited by this paper
• Ocular neovascularization

  1980cited by this paper

• Mast cells in cardiovascular disease: Fibrosis, angiogenesis and atherogenesis.

  2025cites this paper
• MicroRNA biomarkers for predicting treatment response and resistance to bevacizumab in cancer.

  2025cites this paper
• Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology

  2025cites this paper
• The Role of MicroRNA-206 in the Regulation of Diabetic Wound Healing via Hypoxia-Inducible Factor 1-Alpha

  2024cites this paper
• Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo

  2024cites this paper
• Effect of topical motesanib in experimental corneal neovascularization model

  2023cites this paper
• A Network Comprised of miR-15b and miR-29a Is Involved in Vascular Endothelial Growth Factor Pathway Regulation in Thymus Adipose Tissue from Elderly Ischemic Cardiomyopathy Subjects

  2023cites this paper
• Preparation of a Sunitinib loaded microemulsion for ocular delivery and evaluation for the treatment of corneal neovascularization in vitro and in vivo

  2023cites this paper
• Pre-clinical safety of topically administered sunitinib-loaded lipid and polymeric nanocarriers targeting corneal neovascularization.

  2023cites this paper
• Targeting cellular metabolism in head and neck cancer precision medicine era: a promising strategy to overcome therapy resistance.

  2022cites this paper
• Ocular delivery of sunitinib-loaded nanoparticles doped in tragacanthic acid hydrogel in treatment of diabetic retinopathy in rats

  2022cites this paper
• Evaluation of effect of nilotinib in an experimental corneal neovascularization model

  2022cites this paper
• Vascular Endothelial Growth Factor Receptor 2: Molecular Mechanism and Therapeutic Potential in Preeclampsia Comorbidity with Human Immunodeficiency Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Infections

  2022cites this paper
• Eph signaling is regulated by miRNA‐210: Implications for corneal epithelial repair

  2021cites this paper
• The role of bone morphogenetic protein 4 in corneal injury repair.

  2021cites this paper
• Gene Expression Profile of Vascular Endothelial Growth Factors (VEGFs) and Platelet-derived Growth Factors (PDGFs) in the Normal Cornea

  2021cites this paper
• Ocular lamellar crystalline gels for sustained release and enhanced permeation of resveratrol against corneal neovascularization

  2021cites this paper
• Exploring microRNAs in diabetic chronic cutaneous ulcers: Regulatory mechanisms and therapeutic potential

  2020cites this paper
• Molecular approaches for targeted drug delivery towards cancer: A concise review with respect to nanotechnology

  2020cites this paper
• Recent Approaches for Angiogenesis in Search of Successful Tissue Engineering and Regeneration.

  2019cites this paper
• Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.

  2019cites this paper
• Effects of cisplatin-5-fluorouracil combination therapy on oxidative stress, DNA damage, mitochondrial apoptosis, and death receptor signalling in retinal pigment epithelium cells

  2018cites this paper
• Serum miR-30c Level Predicted Cardiotoxicity in Non-small Cell Lung Cancer Patients Treated with Bevacizumab

  2018cites this paper
• MicroRNA-16 inhibits hypoxia-induced vascular endothelial growth factor expression in ARPE-19 cells

  2018cites this paper